Earnings results for Harvard Bioscience (NASDAQ:HBIO)
Harvard Bioscience, Inc. is expected* to report earnings on 03/10/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.04. The reported EPS for the same quarter last year was $0.07.
Analyst Opinion on Harvard Bioscience (NASDAQ:HBIO)
3 Wall Street analysts have issued ratings and price targets for Harvard Bioscience in the last 12 months. Their average twelve-month price target is $4.00, predicting that the stock has a possible downside of 11.11%. The high price target for HBIO is $4.00 and the low price target for HBIO is $4.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Harvard Bioscience has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $4.00, Harvard Bioscience has a forecasted downside of 11.1% from its current price of $4.50. Harvard Bioscience has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Harvard Bioscience (NASDAQ:HBIO)
Harvard Bioscience does not currently pay a dividend. Harvard Bioscience does not have a long track record of dividend growth.
Insiders buying/selling: Harvard Bioscience (NASDAQ:HBIO)
In the past three months, Harvard Bioscience insiders have not sold or bought any company stock. Only 5.40% of the stock of Harvard Bioscience is held by insiders. 64.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Harvard Bioscience (NASDAQ:HBIO
Earnings for Harvard Bioscience are expected to grow by 114.29% in the coming year, from $0.07 to $0.15 per share. The P/E ratio of Harvard Bioscience is -25.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Harvard Bioscience is -25.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Harvard Bioscience has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here